Cardiovascular Intervention and Therapeutics Радиология, ядерная медицина и визуализация

Longitudinal Trends and Outcomes in Transcatheter Aortic Valve Implantation: a report from the SwissTAVI Registry

Thorald Stolte, Jakob Johannes Reichl, David Tueller, Felix Goetzinger, Max Wagener, Stefan Stortecky, Raban Jeger, Oliver Reuthebuch, Stefan Toggweiler, Enrico Ferrari, Peter Wenaweser, Fabian Nietlispach, Christoph Huber, Marco Roffi, Dik Heg, David Meier, Stephan Windecker, Felix Mahfoud, Stephane Noble, Thomas Nestelberger
Springer Nature · 2026-06-15 · DOI 10.1007/s12928-026-01310-1

Аннотация

Abstract The progressive expansion of indications for Transcatheter Aortic Valve Implantation (TAVI) towards lower-risk and younger populations has raised concerns about potential outcome attenuation with increasing procedural volumes. Real-world evidence addressing this concern is limited. To assess temporal trends in patient characteristics and procedural outcomes of TAVI in a large nationwide cohort. The Swiss TAVI Registry prospectively enrolled consecutive patients undergoing TAVI in Switzerland. Baseline characteristics, procedural complications and outcomes were compared across three periods: 2011-2015, 2016-2020 and 2021-2024. The primary endpoint was major adverse cardiovascular events (MACE: all-cause mortality, non-fatal myocardial infarction, and non-fatal stroke) at one year. The secondary endpoint was 30-day MACE. Among 19’452 patients, TAVI volume increased 27% annually. Patient age (82 years) and comorbidity burden remained stable, while the proportion of women increased (51% to 58%) and the median STS score decreased (4.5% to 3.3%). Considering the expansion to lower-risk patients, 1-year MACE declined significantly from 16% to 14% to 9.1% across periods (adjusted HR 0.69, 95% CI 0.62-0.78, p<0.001). Similarly, 30-day MACE decreased from 6.9% to 5.2% to 4.0% (adjusted HR 0.66, 95%CI 0.55-0.78, p<0.001). Procedural mortality declined from 2.9% to 1.2%, periprocedural myocardial infarction from 0.4% to 0.2% and stroke from 3.2% to 2.0% (all p<0.001).Risk-adjusted TAVI outcomes improved continuously despite a significant volume increase, with improvements exceeding those expected from lower-risk patients risk profiles alone.

Читать у издателя →